Edition:
India

Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

575.25INR
16 Feb 2018
Change (% chg)

Rs-0.50 (-0.09%)
Prev Close
Rs575.75
Open
Rs575.40
Day's High
Rs577.55
Day's Low
Rs563.35
Volume
6,640,151
Avg. Vol
5,075,730
52-wk High
Rs729.05
52-wk Low
Rs432.70

Latest Key Developments (Source: Significant Developments)

Beijing Science Sun Pharmaceutical sees FY 2017 net profit to down 15 pct to up 15 pct
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Beijing Science Sun Pharmaceutical Co Ltd <300485.SZ>:Says it sees FY 2017 net profit to decrease by 15 percent to increase by 15 percent, or to be 219.6 million yuan to 297.2 million yuan.Says FY 2016 net profit was 258.4 million yuan.Comments that expanded market and decreased costs as main reasons for the forecast .  Full Article

Sun Pharmaceutical Industries Announces Settlement Of Patent Litigation For Generic Linzess In U.S.
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Sun Pharmaceutical Industries Ltd ::SAYS CO'S UNITS HAVE REACHED AN AGREEMENT WITH IRONWOOD PHARMACEUTICALS, INC. AND ALLERGAN PLC.ANNOUNCES SETTLEMENT OF PATENT LITIGATION FOR GENERIC LINZES IN US.COMPANIES TO GRANT CO'S UNITS LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S FROM FEB 1, 2031 OR EARLIER UNDER CIRCUMSTANCES.ADDITIONAL DETAILS REGARDING THE SETTLEMENT WERE NOT DISCLOSED..  Full Article

Allergan, Ironwood Announce Settlement With Sun Pharma
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Allergan Plc ::IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION.SAYS PER SETTLEMENT TERMS, IRONWOOD, CO TO GRANT UNITS OF SUN PHARMA LICENSE TO MARKET GENERIC VERSION OF LINZESS IN U.S. BEGINNING FEB 1, 2031​.SAYS ‍ADDITIONAL DETAILS REGARDING SETTLEMENT WERE NOT DISCLOSED​.SAYS IRONWOOD PHARMACEUTICALS, CO ANNOUNCED COMPANIES REACHED AN AGREEMENT WITH WHOLLY-OWNED UNITS OF SUN PHARMACEUTICAL INDUSTRIES.SAYS ‍AS A RESULT OF SETTLEMENT, ALL HATCH-WAXMAN LITIGATION BETWEEN COMPANIES AND SUN PHARMA REGARDING LINZESS PATENTS TO BE DISMISSED​.  Full Article

Sun Pharmaceutical Industries Announces U.S FDA Acceptance Of NDA For OTX-101
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Sun Pharmaceutical Industries Ltd ::ANNOUNCES U.S FDA ACCEPTANCE OF NDA FOR OTX-101.  Full Article

Beijing Science Sun Pharmaceutical obtains high-tech enterprise recognition and to enjoy tax preference
Tuesday, 26 Dec 2017 

Dec 26(Reuters) - Beijing Science Sun Pharmaceutical Co Ltd <300485.SZ>:Says it was recognized as high-tech enterprise, and to enjoy a tax preference of 15 percent for three years .  Full Article

Sun Pharma Industries MD says no new updates on Halol; awaiting FDA re-inspection of plants‍​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Sun Pharmaceutical Industries managing director Dilip Shanghvi says::No new updates on halol, awaiting FDA reinspection of plants‍​.  Full Article

Sun Pharma Industries says co expects performance to improve in H2 FY17-18
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Sun Pharmaceutical Industries Ltd ::Says challenging U.S. pricing environment, investments in building global specialty business hit Q2 performance‍​.Says co expects performance to gradually improve in second half of the year.  Full Article

India's Sun Pharmaceutical Industries Sept-qtr consol profit falls 59 pct
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Sun Pharmaceutical Industries Ltd ::Sept quarter consol net profit 9.12 billion rupees versus profit of 22.35 billion rupees last year.Consensus forecast for Sept quarter consol profit was 8.27 billion rupees.Sept quarter consol total revenue from operations 66.50 billion rupees versus 82.60 billion rupees last year.  Full Article

Beijing Science Sun Pharmaceutical announces change in accounting policy
Thursday, 26 Oct 2017 

Oct 26(Reuters) - Beijing Science Sun Pharmaceutical Co Ltd <300485.SZ>:Says it changes accounting policy based on accounting standards for business enterprises No. 16—government subsidies, which was disclosed by the Ministry of Finance on May 10, effective June 12.  Full Article

Sun Pharmaceutical Industries gets U.S.FDA nod for generic Coreg CR‍​
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Sun Pharmaceutical Industries Ltd ::Says gets U.S.FDA nod for generic Coreg CR‍​.  Full Article

Photo

Sun Pharma quarterly profit plunges on weak U.S. sales

India's largest drugmaker Sun Pharmaceutical Industries Ltd reported a 75 percent plunge in third-quarter net profit on Wednesday as pricing pressures in the United States, its biggest market, hit sales.